Skip to Content
  • Title
    EVP, Worldwide Chairman, Pharmaceuticals
  • Affiliation
    Johnson & Johnson
  • Age
    55

Taubert, who was promoted from her role overseeing pharmaceuticals in the Americas in June, runs the drug business that accounted for nearly 50% of the company’s 2017 revenue. In her previous role, she was a key advocate for J&J’s acquisition of Actelion, a $30 billion deal that was completed last summer. In the past 12 months, popular drugs like Darzalex and Imbruvica have led to double-digit growth in Taubert’s pharmaceutical segment and buoyed the company’s total revenue to $76.5 billion.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Personal Information

Previous Rank43
Newcomer?-

Company Financials (2017, or most recently completed fiscal year)

Revenues ($M)76,450
Profits ($M)1,300
Market Value as of 09/18/18 ($M)
377,034.5